Premium
A split face randomized controlled trial comparing 1,064 nm Q‐switched Nd‐YAG laser and modified Kligman’s formulation in patients with melasma in darker skin
Author(s) -
Dev Tanvi,
Sreenivas Vishnubhatla,
Sharma Vinod K.,
Sahni Kanika,
Bhari Neetu,
Sethuraman Gomathy
Publication year - 2020
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.15229
Subject(s) - melasma , medicine , randomized controlled trial , dermatology , adverse effect , surgery
Background No randomized studies compared the efficacy and safety of modified Kligman’s triple combination (TC) with 1,064 nm Q‐switched Nd‐YAG laser (QSNYL) in melasma in darker skin. Objectives To compare the efficacy and safety of QSNYL and TC in the treatment of melasma in Fitzpatrick skin types IV and V. Methods In this split face randomized controlled trial, participants' cheeks were randomized to receive either weekly QSNYL (group A) or daily TC (group B) for 12 weeks, followed by 12 weeks of follow‐up. Results Twenty‐eight patients completed the intervention, and 21 of them completed follow‐up. We found a significant but modest reduction in mean melanin index, modified Melasma Area Severity Index (MASI), and photographic and patient’s assessment in both modalities ( P < 0.01). No significant differences were detected between the groups. All patients had reappearance of pigmentation by the end of follow‐up. Adverse reactions were significantly more in group B ( P < 0.001). Limitation The desired sample size could not be achieved. Conclusion and Relevence No statistically significant differences were observed between QSNYL and TC as monotherapy in melasma. Reappearance of melasma is inevitable after stopping treatment.